From Marginal to Central: Marginal Zone-like B Cells as Critical Targets in Cladribine-Treated Multiple Sclerosis - Scorecard - MDSpire

Transitioning from Marginal to Central: The Role of Marginal Zone-like B Cells as Key Targets in Multiple Sclerosis Patients Treated with Cladribine

  • By

  • Marta Pirronello

  • Mario Picozza

  • Gisella Guerrera

  • Silvia Corbisiero

  • Andrea Misiti

  • Roberta C. Placido

  • Alice Verdiani

  • Lorenzo de Marco

  • Manolo Sambucci

  • Elena Olivieri

  • Daniela F. Angelini

  • Esmeralda Quartuccio

  • Luca Prosperini

  • Carla Tortorella

  • Maria C. Buscarinu

  • Valeria Zancan

  • Francesca de Masi

  • Marco Salvetti

  • Claudio Gasperini

  • Giovanna Borsellino

  • Luca Battistini

  • June 18, 2026

Share

Clinical Scorecard: Transitioning from Marginal to Central: The Role of Marginal Zone-like B Cells as Key Targets in Multiple Sclerosis Patients Treated with Cladribine

At a Glance

CategoryDetail
ConditionMultiple Sclerosis
Key MechanismsRole of B lymphocytes, particularly marginal zone-like memory B cells, in MS pathogenesis and treatment response.
Target PopulationPersons with Multiple Sclerosis (pwMS) undergoing cladribine treatment.
Care SettingClinical research setting involving longitudinal monitoring of MS patients.

Key Highlights

  • Cladribine preferentially depletes memory B cells while sparing naïve B cells.
  • Marginal zone-like memory B cells exhibit a significant proinflammatory capacity.
  • Persistence of oligoclonal bands during remission indicates ongoing B-cell activity.
  • B-cell-targeted therapies have transformed MS treatment outcomes.
  • The study investigates B-cell subset dynamics over several years post-cladribine treatment.

Guideline-Based Recommendations

Diagnosis

  • Utilize serum neurofilament light chain (NfL) as a marker of neuroaxonal injury and MS disease activity.
  • Assess for intrathecal IgG and IgM oligoclonal bands to evaluate immune activation.

Management

  • Consider cladribine for its efficacy in depleting proinflammatory B-cell subsets.

Monitoring & Follow-up

  • Longitudinal monitoring of B-cell subsets and serum NfL levels during and after treatment.

Risks

  • Potential for persistent oligoclonal bands despite clinical remission.

Patient & Prescribing Data

36 persons with MS, median age 39, with varying prior disease-modifying therapy exposure.

Cladribine treatment involves two cycles over two years, with specific dosing based on body weight.

Clinical Best Practices

  • Monitor B-cell subset reconstitution and cytokine production post-cladribine treatment.
  • Evaluate the presence of oligoclonal bands as part of routine MS management.

Related Resources & Content

Original Source(s)

Related Content